Komori
Revision of earnings forecasts4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Revisions to Earnings Forecasts

The full-year consolidated earnings forecast for the fiscal year ending March 2027 has been revised upward. Net sales have been raised to ¥2,800 million, operating profit to ¥1,200 million, ordinary profit to ¥1,300 million, and net income attributable to owners of the parent to ¥700 million, respectively, from the previous forecast.

Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
2800
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Full yearPrevious forecast published 13 May 2026
Net Sales369,500→372,300million
+0.8%
Operating profit43,800→45,000million
+2.7%
Ordinary income46,100→47,400million
+2.8%
Profit attributable to owners of the parent34,500→35,200million
+2.0%
Net income per share152.68→155.78yen and sen
+2.0%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

The assumed exchange rates were revised from ¥155 to ¥158 per US dollar and from ¥22 to ¥23 per Chinese yuan, and the Asia, Japan and Europe segments performed strongly and exceeded expectations during the cumulative first quarter of the consolidated fiscal year.

Previous-period resultsNet sales: ¥343,725 million; operating profit: ¥41,118 million; ordinary profit: ¥47,971 million; net income attributable to owners of the parent: ¥34,247 million; net income per share: ¥151.56
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥369,500 million → ¥372,300 million(+0.8%)
Operating profit¥43,800 million → ¥45,000 million(+2.7%)
Ordinary income¥46,100 million → ¥47,400 million(+2.8%)
Profit attributable to owners of the parent¥34,500 million → ¥35,200 million(+2.0%)
Net income per share152.68 yen and sen → 155.78 yen and sen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredFull year
Publication date of previous forecast13 May 2026
Previous-period resultsNet sales: ¥343,725 million; operating profit: ¥41,118 million; ordinary profit: ¥47,971 million; net income attributable to owners of the parent: ¥34,247 million; net income per share: ¥151.56
Reason for the revisionThe assumed exchange rates were revised from ¥155 to ¥158 per US dollar and from ¥22 to ¥23 per Chinese yuan, and the Asia, Japan and Europe segments performed strongly and exceeded expectations during the cumulative first quarter of the consolidated fiscal year.
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In addition to revising the assumed exchange rates from ¥155 to ¥158 per US dollar and from ¥22 to ¥23 per Chinese yuan, the Asia, Japan and Europe segments performed strongly and exceeded expectations during the cumulative first quarter.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revisions to Earnings Forecasts | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori